Literature DB >> 22949777

Remission of chronic anthracycline-induced heart failure with support from a continuous-flow left ventricular assist device.

Nadeem Khan1, Syed Arman Husain, Syed Iman Husain, Natalia Khalaf, Joggy George, Farshad Raissi, Ana Maria Segura, Biswajit Kar, Roberta C Bogaev, O H Frazier.   

Abstract

We report the case of a patient who had chronic anthracycline-induced cardiomyopathy that was reversed after treatment with a left ventricular assist device. A 29-year-old woman had undergone anthracycline-based chemotherapy as a teenager in 1991 and 1992 and received a diagnosis of dilated cardiomyopathy 10 years later. Optimal medical therapy had initially controlled the symptoms of heart failure. However, in June 2006, the symptoms worsened to New York Heart Association functional class IV status. We implanted a continuous-flow left ventricular assist device as a bridge to cardiac transplantation; of note, a left ventricular core biopsy at that time showed no replacement fibrosis. The patient's clinical status improved thereafter, enabling left ventricular assist device ex-plantation after 17 months. To our knowledge, this is the first report of the use of left ventricular assist device support to reverse chronic anthracycline-induced heart failure.

Entities:  

Keywords:  Anthracyclines/adverse effects; cardiomyopathies/chemically induced; heart failure/chemically induced; heart-assist devices; heart/drug effects; recovery of function; treatment outcome; ventricular dysfunction, left

Mesh:

Substances:

Year:  2012        PMID: 22949777      PMCID: PMC3423291     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  9 in total

1.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Gaia De Giacomi; Mara Rubino; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  J Am Coll Cardiol       Date:  2010-01-19       Impact factor: 24.094

2.  Doxorubicin-induced cardiomyopathy 17 years after chemotherapy.

Authors:  Simi Kumar; Ravi Marfatia; Susan Tannenbaum; Clifford Yang; Erick Avelar
Journal:  Tex Heart Inst J       Date:  2012

3.  Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy.

Authors:  John Rickard; Dharam J Kumbhani; Bryan Baranowski; David O Martin; Wilson H Tang; Bruce L Wilkoff
Journal:  Am J Cardiol       Date:  2010-02-15       Impact factor: 2.778

Review 4.  Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.

Authors:  Genzou Takemura; Hisayoshi Fujiwara
Journal:  Prog Cardiovasc Dis       Date:  2007 Mar-Apr       Impact factor: 8.194

Review 5.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

6.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

7.  Recovery of ventricular function with a left ventricular axial pump in a patient with end-stage toxic cardiomyopathy not a candidate for heart transplantation: first experience in Spain.

Authors:  E Castells; J Roca; A Miralles; N Manito; D Ortiz; J Gonzalez; J Granados; M Benito; M Rabasa; F S'braga; J Toscano; D Toral; A López; C Fontanillas
Journal:  Transplant Proc       Date:  2009 Jul-Aug       Impact factor: 1.066

8.  Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device.

Authors:  Mark Freilich; Dion Stub; Donald Esmore; Justin Negri; Robert Salamonsen; Peter Bergin; Angeline Leet; Meroula Richardson; Andrew Taylor; John Woodard; David Kaye; Franklin Rosenfeldt
Journal:  J Heart Lung Transplant       Date:  2009-01       Impact factor: 10.247

9.  Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy.

Authors:  Olujimi A Ajijola; K Veena Nandigam; Bruce A Chabner; Mary Orencole; G William Dec; Jeremy N Ruskin; Jagmeet P Singh
Journal:  Am J Cardiol       Date:  2008-03-10       Impact factor: 2.778

  9 in total
  3 in total

1.  Titanium Plug Closure after HeartWare Ventricular Assist Device Explantation in a 15-Year-Old Girl: First U.S. Experience.

Authors:  Diego A Lara; Aamir Jeewa; Barbara A Elias; Elizabeth O McCullum; Susan W Denfield; William J Dreyer; Iki Adachi
Journal:  Tex Heart Inst J       Date:  2017-02-01

2.  Management of Advanced Heart Failure due to Cancer Therapy: the Present Role of Mechanical Circulatory Support and Cardiac Transplantation.

Authors:  Salil V Deo; Sadeer G Al-Kindi; Guilherme H Oliveira
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

Review 3.  Orthotopic Heart Transplantation and Mechanical Circulatory Support in Cancer Survivors: Challenges and Outcomes.

Authors:  Nina Ghosh; John Hilton
Journal:  J Oncol       Date:  2015-08-03       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.